Investing involves risk, including possible loss of principal. Investment in
emerging market countries may involve heightened risks such as increased
volatility and lower trading volume, and may be subject to a greater risk of
loss than investment in a developed country. Please carefully consider the
Fund's investment objectives, risk factors, and charges and expenses before
investing. This and other information can be found in the relevant Fund's
prospectus. Please read the prospectus carefully before investing. ChinaAMC
Funds are not sponsored, endorsed, issued, sold or promoted by their index
providers (only applicable to ETFs and index funds). For details of an index
provider including any disclaimer, please refer to the relevant ChinaAMC Fund
offering documents.
Source: Fund performance and index data are
provided by ChinaAMC and the relevant index providers (if applicable)
respectively. This website is prepared by China Asset Management (Hong Kong)
Limited and has not been reviewed by the Securities and Futures Commission.
Hang Seng Index Disclaimer
The mark and name Hang Seng Hong Kong-Listed Biotech Index, Hang Seng TECH Index and Hang Seng Stock Connect Hong Kong SmallCap Index are proprietary to Hang Seng Data Services Limited (“HSDS”) which has licensed its compilation and publication to Hang Seng Indexes Company Limited (“HSIL”). HSIL and HSDS have agreed to the use of, and reference to Hang Seng Hong Kong-Listed Biotech Index, Hang Seng TECH Index and Hang Seng Stock Connect Hong Kong SmallCap Index by China Asset Management (Hong Kong) Limited (“the Issuer”) in connection with the ChinaAMC Hong Kong Biotech Index ETF, ChinaAMC Hang Seng TECH Index ETF and ChinaAMC Hang Seng Stock Connect Hong Kong SmallCap Index ETF (the “Product”). However, neither HSIL nor HSDS warrants, represents or guarantees to any person the accuracy or completeness of the Hang Seng Hong Kong-Listed Biotech Index, Hang Seng TECH Index and Hang Seng Stock Connect Hong Kong SmallCap Index, its computation or any information related thereto and no warranty, representation or guarantee of any kind whatsoever relating to the Hang Seng Hong Kong-Listed Biotech Index, Hang Seng TECH Index and Hang Seng Stock Connect Hong Kong SmallCap Index are given or may be implied. Neither HSIL nor HSDS accepts any responsibility or liability for any economic or other loss which may be directly or indirectly sustained by any person as a result of or in connection with the use of and/or reference to the Hang Seng Hong Kong-Listed Biotech Index, Hang Seng TECH Index and Hang Seng Stock Connect Hong Kong SmallCap Index by the Issuer in connection with the Product, or any inaccuracies, omissions or errors of HSIL in computing the Hang Seng Hong Kong-Listed Biotech Index, Hang Seng TECH Index and Hang Seng Stock Connect Hong Kong SmallCap Index. Any person dealing with the Product shall place no reliance whatsoever on HSIL and/or HSDS nor bring any claims or legal proceedings against HSIL and/or HSDS in any manner whatsoever. For the avoidance of doubt, this disclaimer does not create any contractual or quasi-contractual relationship between any broker or other person dealing with the Product and HSIL and/or HSDS and must not be construed to have created such relationship.
NASDAQ 100 Index Disclaimer
The Product(s) is not sponsored, endorsed, sold or promoted by NASDAQ, Inc. or
its affiliates (NASDAQ, Inc. with its affiliates, is referred to as “NASDAQ”).
NASDAQ has not passed on the legality or suitability of, or the accuracy or
adequacy of descriptions and disclosures relating to, the Product. NASDAQ makes
no representation or warranty, express or implied, to the owners of shares of
the Product or any member of the public regarding the advisability of investing
in securities generally or in the Product particularly or the ability of the
Index to track general stock market performance. NASDAQ's only relationship to
the Product and China Asset Management (Hong Kong) Limited (“ChinaAMC”) is in
the licensing of certain trademarks and trade names of NASDAQ and of the Index
which is determined, composed and calculated by NASDAQ without regard to
ChinaAMC or the Product. NASDAQ QMX has no obligation to take the needs of
ChinaAMC or its affiliates or the owners of shares of the Product into
consideration in determining, composing or calculating the Index. NASDAQ is not
responsible for and has not participated in the determination of the prices and
amount of shares of the Product, or the timing of the issuance or sale of such
shares or in the determination or calculation of the equation by which shares of
the Product are to be converted into cash. NASDAQ has no obligation or liability
in connection with the administration, marketing or trading of the
Product.
NASDAQ does not guarantee the accuracy and/or uninterrupted calculation of the
index or any data included therein. Nasdaq makes no warranty, express or
implied, as to results to be obtained by the trust on behalf of the product as
licensee, licensee's customers and counterparties, owners of the shares of the
product, or any other person or entity from the use of the subject index or any
data included therein in connection with the rights licensed as described herein
or for any other use. NASDAQ makes no express or implied warranties and hereby
expressly disclaims all warranties of merchantability or fitness for a
particular purpose or use with respect to the index or any data included
therein. Without limiting any of the foregoing, in no event shall NASDAQ have
any liability for any direct, indirect, special, punitive, consequential or any
other damages (including lost profits) even if notified of the possibility of
such damages.
CSI Index Disclaimer
All rights in the CSI 300 Index (“Index”) vest in China Securities Index Company (“CSI”). “CSI 300®” is a trade mark of CSI. CSI does not make any warranties, express or implied, regarding the accuracy or completeness of any data related to the Index. CSI is not liable to any person for any error of the Index (whether due to negligence or otherwise), nor shall it be under any obligation to advise any person of any error therein. The Fund based on the Index is in no way sponsored, endorsed, sold or promoted by CSI and CSI shall not have any liability with respect thereto.
Bloomberg Barclays China Treasury + Policy Bank Bond Index Disclaimer
BLOOMBERG® is a trademark and service mark of Bloomberg Finance L.P. and its affiliates (collectively “Bloomberg”). BARCLAYS® is a trademark and service mark of Barclays Bank Plc (collectively with its affiliates, “Barclays”), used under license. Bloomberg or Bloomberg's licensors, including Barclays, own all proprietary rights in the Bloomberg Barclays Indices. Neither Bloomberg nor Barclays is affiliated with China Asset Management (Hong Kong) Limited, and neither approves, endorses, reviews or recommends ChinaAMC Bloomberg Barclays China Treasury + Policy Bank Bond Index ETF. Neither Bloomberg nor Barclays guarantees the timeliness, accurateness or completeness of any data or information relating to Bloomberg Barclays China Treasury + Policy Bank Index, and neither shall be liable in any way to the China Asset Management(Hong Kong) Limited, investors in ChinaAMC Bloomberg Barclays China Treasury + Policy Bank Bond Index ETF or other third parties in respect of the use or accuracy of the Bloomberg Barclays China Treasury + Policy Bank Index or any data included therein.
MSCI Index Disclaimer
The funds or securities referred to herein are not sponsored, endorsed, or promoted by MSCI, and MSCI bears no liability with respect to any such funds or securities or any index on which such funds or securities are based. The Prospectus contains a more detailed description of the limited relationship MSCI has with China Asset Management (Hong Kong) Limited and any related funds.
本網站的資料乃由華夏基金(香港)有限公司(簡稱「華夏(香港)」)編制,僅供參閱用途。本網站有關基金的內容不適用於在限制該內容之發佈的區域居住之人士。就任何不獲授權進行分銷或要約的任何司法管轄區,本網站所載資料並不構成任何證券的分銷,買賣的要約,或促使買賣的要約。
本網站所載之基金(簡稱「基金」)已獲證監會認可向香港公眾人士全面銷售;其所載之任何內容亦未經證監會審閱。
本網站所提及的任何內容均不構成對基金的任何股份的投資邀約,也不構成對於任何證券的買賣或進行任何交易的投資建議。在使用本網站所載資料以前,閣下須根據個人狀況,確定任何投資,證券或策略是否合適閣下;如有須要,應諮詢獨立專業意見。
投資涉及風險,基金單位價格可升亦可跌,基金過往業績並不表示將來的回報。基金的價值可能會非常波動,並可能於短時間內大幅下跌,閣下亦可能損失全數投資金額。投資者應參閱有關基金之配售備忘錄,以了解基金詳情及風險因素,特別是投資於中國市場所涉及之風險。本基金可投資於洐生工具或結構性產品;該等投資工具可涉及重大風險,例如交易對手違約風險,有可能引致基金蒙受嚴重損失。
華夏(香港)已盡其所知使本網站所載資料在發佈之時準確 ;但華夏(香港)並不保證有關資料的準確性及完備性。華夏(香港),其聯營公司,董事,高級職員及僱員對此網站所提供的資料的任何相關錯誤或遺漏並不負責。華夏(香港)亦對於因使用此網站內容而引致或引發的任何損失或代價不承擔責任。
與本網頁所載資料有關的所有版權,專利權及其他產權均為華夏(香港)或其聯屬公司所有。在未經華夏(香港)同意下,不得複印,分發或複製本網頁內之任何資料或任何部分。
Investment involves risks, including the loss of principle. Past performance is not indicative of future results. Before investing in below products, investor should refer to the Fund's prospectus for details, including the risk factors. You should not make investment decision based on the information on this material alone. Please note:
The Index consists of 100 of the largest U.S. and international non-financial companies listed on The NASDAQ.
Provides comprehensive Nasdaq-100 Index ETF and Leveraged/Inverse Product Suites, ranging from physical ETF (3086 HK), leveraged (2x) (7261 HK), inverse (-1x) (7331 HK) to inverse (-2x) (7522 HK). This product series also allows trading in Asian time zones.
ChinaAMC(HK) issued Asian's first two NASDAQ-100 Index daily (2x) leveraged and (-1x) inverse products in Hong Kong in 2016. ChinaAMC's name is made in the field and it has extensive managerial experience.
*The product is a synthetic product
About
Leveraged
and Inverse
(“L&I”) Products
Features
Daily
Rebalancing
Comparison with
other investment
products
ChinaAMC
Leveraged and
Inverse Product
Series
L&I Products are structured as Exchange Traded Funds (ETFs) and seek to achieve short-term investment results that correspond to the magnified or inverse performance of their underlying benchmarks on a daily basis.
Seek to provide the leveraged (up to 2x) daily performance of their benchmark
Seek to provide the inverse (up to -2x) daily performance of their benchmark
Grasp your opportunity in a bull market. Leveraged Products seek to achieve a leveraged daily return (2x) of the benchmark's daily performance, before fees and expenses
Take hold of your opportunity in a bear market. Inverse Products seeks to achieve an inverse daily return (-1x)/(-2x) of the benchmark's daily performance, before fees and expenses
Leveraged Products seek to provide two times (2x) the daily performance of their benchmark
Seek to provide the Inverse (-1x) (up to 2x) daily performance of their benchmark
Seek to provide the inverse (-2x) daily performance of their benchmark
Take ChinaAMC NASDAQ-100 Index Daily (2X) Leveraged as an
example. If the index goes up by 1%, the daily (2X)
leveraged product will gain a daily return of
2%.
On the other hand, when the index drops
by 1%, the daily (2X) leveraged product will have a
daily loss of 2%.
Take ChinaAMC NASDAQ-100 Index daily (-1X) and (-2X)
inverse as an example. When the index drops by 1%, the
daily (-1X) inverse product will have a daily gain of 1%
whereas the daily (-2X) inverse product will have a
daily gain of 2%.
On the other hand, if the
index goes up by 1%, the daily (-1X) inverse product
will have a daily loss of 1%.
Note: For illustration only.
Note: For illustration only.
Leveraged and Inverse products will conduct daily adjustment at or around market close, to ensure the product can maintain the exposure ratio.
Product Asset
Total Exposure
Product Asset
Total Exposure
L&I products are not affected by expiration date, decay of time value, implied volatility and no Knock out feature
Loss of L&I products is limited to the amount invested and the positions would not be liquidated if the market moves against your position